🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

A new Parliament sits today If they want to think about a Cancer Plan - here's a starter for 10 The Lancet Oncology Pressure points explored and recommendations offered thelancet.com/journals/lanon…

Thank you for your generosity of time to come & speak at the patient summit & for answering the questions from the audience. Sheeba Irshad #SBCSummit2024

Great #SBCSummit2024 conference dinner last night at the Museum of Liverpool it is very clear women & men living secondary breast cancer are hungry for knowledge but also want to partner with the clinical & scientific community to improve care & to drive forward research

Thanks Phil Walker for being on the panel chaired by Lesley Fallowfield & quote of the day was ‘everybody needs a Phil’ The Clatterbridge Cancer Centre patients with MBC lucky to have access to specific CNS support. Not the case everywhere very sadly Make 2nds Count Lesley Stephen. #SBCsummit2024

A massive thank you to Rik Hall & Monster Films for providing a film crew pro bono to film & interview attendees at the secondary breast cancer summit 2024. Look forward to seeing the finished product. The Clatterbridge Cancer Centre Liverpool ECMC #SBCSummit2024

Massive thank you to all our chairs & speakers for their time to come along & present & answer questions from our attendees Some of our day 2 speakers Naman Julka-Anderson (he/him/his) 💙 Daniel Monnery The Urban Kitchen & Chair, Dr Marina Parton #SBCsummit2024

Be the change ⁦ABC Global Alliance⁩ #actabc youtu.be/7vklNEhEDxE?fe…

There are always other victims of advanced breast cancer ⁦ABC Global Alliance⁩ #actabc youtu.be/-xzzrIheW1I?fe…

Refer early to Enhanced supportive care improves outcomes & saves money Daniel Monnery not all hospitals like The Clatterbridge Cancer Centre have such services. As Dan said women & men living with treatable but not curable cancer need to contact their cancer alliances if they don’t have such services

Key thing women brought up at the #SBCsummit2024 was inequity-inequity in regards to 1. T-Dxd for HER2 low 🏴󠁧󠁢󠁳󠁣󠁴󠁿✔️ 🏴󠁧󠁢󠁥󠁮󠁧󠁿❌ 2. Access to secondary breast cancer CNS support 3. Aceess to clinical trials & 4. Access to enhanced supportive care. Same taxes, should mean same services.

Latest paper: Structural rearrangements in BC brain metastases (BCBM). Most common involves CDK12 & predominantly seen in HER2+ BCBMs. Role of CDK12 needs further work & underlines importance of accessing BCBM DNA either via BCBM tissue or ctDNA in CSF. ascopubs.org/doi/pdf/10.120…

The evolving workforce crisis in cancer NHS England showing fill rates for clinical & medical oncology speciality training just above 50% & trend ⬇️ ➕The Royal College of Radiologists census data on Clin Onc consultant shortage. Recruit, Train & Retain 🗝️ to 🛑 this crisis worsening

CEO Wellcome John-Arne Røttingen highlights the issues in clinical research in the UK. Research is good for patients & good for UK economically. Research needs to be weaved into the fabric of routine clinical practice & seen as intrinsic to & inseparable from good care.

End of life criteria vs severity modifier. Agents previously approved by NICE with EoL criteria would struggle with SM. T-Dxd for HER-2 low for MBC has fallen short using SM. Appears for MBC either price needs to be reduced and/or the QALY weighting/modifier changed.

NICE’s severity modifier: a step in the right direction, but still a long way to go. Article notes for NICE ‘severity categories that are eligible tor a QALY weight are higher than severity categories applied elsewhere in the world’. ohe.org/insight/nices-…

Innovation vs cost & sustainability of new cancer drugs Financial Times timely as we head into ⁦⁦ESMO - Eur. Oncology⁩ 2024 personalised reimbursement model, programmes linking payment to the performance, de-escalation studies & pharma fulling social contract all key on.ft.com/3ARFoVI

Look forward to CoBrCa Congress ABS & debating against the motion that all stage 2 & 3 TNBC should be treated according to the KEYNOTE-522 regimen. Thinking about, prodding & poking studies their design & data is a vital part of oncology. Will share some thoughts post debate

French philosopher Claude Lévi-Strauss said: "The scientist is not a person who gives the right answers, he is one who asks the right questions." #CoBrCa2024 has been a fabulous meeting addressing multiple #breastcancer controversies Thank you faculty. I have more questions!

Lay summary DB-12: Primary endpoint varied by arm BM: PFS (=Median 17.3mths; 95% CI 13.7-22.1) & no-BM: ORR (=62.7%; 95% CI: 56.5– 68.8). Adds to CNS activity data for T-Dxd. Key issue moving forward will possible radionecrosis in BM group, all need to be aware & research needed

KEYNOTE-522: Significant improvement in Overall survival (HR: 0.66 (95% CI, 0.50-0.87), p=0.00150. 5-yr rate Pembro: 86.6% (84.0-88.8) vs Placebo: 81.7% (77.5-85.2). 👍🏻👍🏻One key question Is do patients with a pCR need pembro in adjuvant phase. #ESMO24